Highest-materiality recent filing
ImmuCell Q2 2026 net income $1.8M, revenue up 11.5% to $7.2M
Net income $1.8M ($0.20 diluted EPS) vs $0.5M ($0.06) in Q2 2025; adjusted EBITDA $2.7M vs $1.4M.
ImmuCell Q2 product sales rise 11.5% to $7.2M; domestic sales up 27.7% YoY
Q2 2026 total product sales $7.2M vs $6.4M in Q2 2025, an 11.5% increase.
ImmuCell Board authorizes $3.5M First Defense capacity expansion, converting former Re-Tain facility
Board authorized first phase: renovate former Re-Tain facility and add new freeze dryer.
ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M
Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
ImmuCell settles Norbrook dispute, to receive $2M payment
ImmuCell and Norbrook entered a Settlement Deed on May 8, 2026 resolving all claims from a 2019 Development and Supply Agreement.
ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%
Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.
ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M
Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.
ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain
Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.
ImmuCell pauses Re-Tain after FDA incomplete letter, shifts focus to First Defense; $2.3M impairment
FDA issued Incomplete Letter for Re-Tain NADA on Dec 23 due to contract manufacturer inspection issues; four of five Technical Sections had Complete Letters.
ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%
Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.
ImmuCell names Olivier te Boekhorst CEO; board expanded to nine directors
Olivier te Boekhorst started as President and CEO on Nov 1, 2025, succeeding Michael Brigham.
ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M
Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.
ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025
Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.
ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M
Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.
ImmuCell refinances bank debt with $2.3M loan at 6.5%, extending to 2030
New $2,327,119 loan at 6.5% fixed from Maine Community Bank; pays off prior loans at 7% and 8%.
ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared
Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.
ImmuCell CEO Michael Brigham plans retirement by early 2026; board launches succession search
President/CEO Michael Brigham (65) intends to retire from full-time work by early 2026; board has started successor search.
ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago
Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).
ImmuCell appoints Timothy C. Fiori as CFO effective April 7, 2025
Fiori served 24 years at IDEXX Laboratories, most recently as Senior Director Finance, Commercial Operations.
ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago
Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.
ImmuCell settles insurance claim for $426,587; total recovery $676,587 from contamination events
Settlement of $426,587 received for production contamination losses from late 2022 through April 2024.
ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M
Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).
Norbrook will complete manufacture of current in-process inventory.
ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M
Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).
ImmuCell Q2 product sales up 55% but net loss $1.5M; FDA incomplete letter for Re-Tain
Product sales $5.5M (+55% YoY); six-month sales $12.7M (+82% YoY).
ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%
Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.
ImmuCell provides Re-Tain® FDA update; NADA submission after contract manufacturer clearance
Received FDA Incomplete Letter on CMC Technical Section for Re-Tain®; fourth submission prepared.
ImmuCell Q1 2024: Record sales $7.3M (+111% YoY); net loss narrows; FDA delays Re-Tain
Product sales of $7.3M, up 111% YoY from $3.4M; all-time quarterly record.
ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY
Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.
ImmuCell enters ATM offering agreement for up to $11M common stock with Craig-Hallum
Company entered into ATM offering agreement with Craig-Hallum for up to $11M of common stock.
ImmuCell amends supply agreement: Re-Tain deal terminates Nov 30, 2024 if FDA not approved
Agreement auto-terminates on Nov 30, 2024 unless FDA approval for Re-Tain is received by then.
ImmuCell FY2023 net loss widens to $5.8M; Q4 sales up 30% but margin pressured
Net loss $5.8M ($0.75 per share) in FY2023 vs $2.5M ($0.32) prior year.
ImmuCell reports Q4 2023 product sales of $5.1M, up 30% YoY; backlog grows to $9.4M
Q4 2023 sales $5.1M vs $3.9M in Q4 2022 (+30.3%); full-year 2023 sales $17.5M vs $18.6M (-5.9%).
Product sales $5.4M (+13% YoY) for Q3 2023; nine-month sales $12.4M (-16% YoY).
ImmuCell Q3 preliminary sales $5.4M (+13% YoY); backlog rises to $8.9M
Q3 2023 total sales $5.40M, up 13% from $4.80M in Q3 2022.
The Board of Directors of ImmuCell Corporation (the Company) has elected Timothy C. Fiori, age 46, to serve as its Chief Financial Officer effective April 7, 2025.
Pursuant to a recommendation by the Nominating Committee, the board of directors (the “Board”) of ImmuCell Corporation (the “Company”) elected Mr. Bryan K. Gathagan as an independent director, effective June 16, 2023.
On January 24, 2023, David S. Cunningham notified ImmuCell Corporation (the “Company”) of his intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2023 Annual Meeting to be held on June 15, 2023.
On February 11, 2022, Dr. Joseph H. Crabb resigned from all positions he held at the Company, including without limitation as an employee and an officer of the Company.
Max materiality 0.85 · Median 0.60 · Most common event earnings